[1] Del Guerra S, et al. Diabetes 2005,54(3):727-735; 2 Li C,et al. J Biol Chem 2013,288(6):3938-3951.[2] HeM, WuN, LeongMC, et al. miR-145 improves metabolic inflammatory disease through multiple pathways[J]. J Mol Cell Biol, 2019, Pii: mj2015.[3] MoatesJM, NandaS, CissellMA, et al. BETA2 activates transcription from the upstream glucokinase gene promoter in islet beta-cells and gut endocrine cells[J]. Diabetes, 2003, 52(2):403-408.[4] NakagawaY, NagasawaM, MedinaJ, et al. Glucose evokes rapid Ca2+ and cyclic AMP signals by activating the cell-surface glucose-sensing receptor in pancreatic β-cells[J]. PLoS One, 2015,10(12):e0144053.[5] F.M. Matschinsky. M.A. Magnuson Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. p66-67. ISBN 3–8055–7744–3.[6] NjølstadPR, SagenJV, BjørkhaugL, et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway[J]. Diabetes, 2003,52(11):2854-2860.[7] 沈贵兰, 郑芸, 孔海平. 1例新生儿持续性高胰岛素血症性低血糖症的护理[J]. 健康必读旬刊, 2013(9):96-96.[8] Byrne MM,et al. J Clin Invest. 1994,93(3):1120-30.[9] Haeusler RA, et al. Mol Metab 2014,4(3):222-226.[10] Haeusler RA, Camastra S, Astiarraga B, et al. Decreased expression of hepatic glucokinase in type 2 diabetes[J]. Mol Metab, 2015,4(3):222-226.[11] Basco D, et al. Nat Commun 2018,9(1):546.